Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... to maintain acceptable therapeutic blood concentrations without a boosting agent such as ritonavir. It will also be used to determine doses for subsequent studies in HIV-infected ...
2009 NOV 2 ... Erythromycin, Diltiazem, cLarithromycin, Itraconazole, Voriconazole, colchicinE, Ritonavir) pneumonic was established." Mckinnell and colleagues published their ...
2009 NOV 25 ... therapeutic agent. To test the above hypothesis, the biophysical interactions of ritonavir-loaded poly(L-lactide) nanoparticles (RNPs), conjugated to either a TAT peptide ...
2009 NOV 1 ... HIV strains resistant to other available PIs." "Coadministration with ritonavir (RTV) improves the oral bioavailability of DRV. Inhibition of cytochrome P450 by RTV has ...
2009 NOV 1 ... A second clinical study will test aprepitant as an antiviral agent in combination with ritonavir, another anti-HIV drug, in patients failing HIV therapy. The interactions between both ...
2009 NOV 9 ... regimen than with a twice-daily regimen (e. g., once-daily versus twice-daily lopinavir/ritonavir). Although resistance is a concern for patients taking non-nucleoside reverse ...
2009 NOV 9 ... objective of this study was to determine the influence of a 2-week course of lopinavir-ritonavir on the pharmacokinetics of the triglyceride-lowering agent, gemfibrozil. The study was ...
2009 NOV 16 ... States, "To identify pharmacokinetic (PK) drug-drug interactions between tipranavir-ritonavir (TPV/r) and rosuvastatin and atorvastatin, we conducted two prospective, open-label, ...
2009 NOV 1 ... between the benzimidazoles albendazole and mebendazole and the potent CYP3A4 inhibitor ritonavir. Sixteen healthy volunteers were administered a single oral dose of 1,000 mg mebendazole ...
2009 NOV 23 ... We examined the pharmacokinetics of rifabutin before and after the addition of lopinavir-ritonavir." "We analyzed 10 patients with HIV infection and active tuberculosis in ...
2009 NOV 1 ... discuss in 'Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage' new findings in HIV/AIDS. "Several drug ...
2009 NOV 1 ... "Participants received atazanavir 400 mg daily for 7 days followed by atazanavir/ritonavir 300 mg/100 mg daily for 7 days with pharmacokinetic studies on days 7 and 14. Other ...
2009 NOV 9 ... of endogenous glucose production (EGP). We tested the acute effects of 3 PIs, indinavir, ritonavir, and amprenavir, on EGP quantified by stable isotope techniques during the ...
2009 NOV 23 ... the safety and efficacy of a regimen containing raltegravir, etravirine, and darunavir/ritonavir for treatment-experienced patients infected with multidrug-resistant HIV," ...
2009 NOV 9 ... finally achieved with a combination of lamivudine, abacavir, efavirenz, and lopinavir/ritonavir." Dinavahi and colleagues published their study in Kidney International ...
2009 NOV 1 ... were enrolled. More rapid increases in IS plasma C-t were observed 48 h after initiating ritonavir (RTV)-boosted PI therapy post-LTx than when using unboosted PIs. Seven patients ...
2009 NOV 16 ... oral HCV protease inhibitor that achieves once-daily dosing through the use of low-dose ritonavir as a metabolic inhibitor. The NEXT-1 study evaluates 12 weeks of narlaprevir 200 mg or ...
2009 NOV 23 ... in 'Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial,' new data ...
2009 NOV 1 ... presented in the report 'Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.' According to recent research from Bangkok, Thailand, ...
